AbbVie lifts guidance despite slump in Humira sales

AbbVie (NYSE:ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology drugs offset a sharp sales decline for its blockbuster arthritis therapy Humira.

The North Chicago, Illinois-based pharma giant reported $15.4B in revenue for the quarter with ~7% YoY growth, exceeding the consensus by $390M as its immunology portfolio added $7.6B to the topline with ~10% YoY growth.

While Humira net revenues slumped 58% YoY to $1.2B, Skyrizi and Rinvoq, which ABBV has readied as potential replacements for the antibody therapy that lost its U.S. market exclusivity in 2023, brought in $4.4B and $2.0B, respectively, with ~62% YoY and ~42% YoY growth.

Meanwhile, AbbVie’s (NYSE:ABBV) neuroscience portfolio generated $2.7B in net revenue with ~24% YoY growth, and its oncology portfolio added $1.7B to the topline with ~3% YoY growth despite a 10% YoY sales decline for the company’s leukemia therapy Imbruvica, developed with J&J (JNJ).

On an adjusted basis, ABBV recorded 84.4% of gross margin and 44.3% of operating margin for the quarter, and its non-GAAP earnings per share for the period grew ~12% YoY to $2.97, topping the consensus by $0.06.

The company’s revised outlook for non-GAAP earnings per share for 2025 indicates $11.88 – $12.08, up from $11.67 – $11.87 in the prior forecast and $11.98 in the consensus.